Background. With increased use of immune checkpoint inhibitors (ICIs) among cancer patients, there is substantial interest in understanding clinical, economics outcomes and management of immune-related adverse events (irAEs). Patients and Methods. A retrospective study was conducted using Premier Healthcare Database, a US national hospital discharge database, from March 1, 2015 through December 31, 2017. The database comprises more than 880 million inpatient and hospital-based outpatient encounters with more than 200 million unique patients reported by 966 hospitals. Patients with four solid tumors known to benefit from ICI therapy were included. The list of irAEs assessed were defined a priori per ASCO clinical guidelines for irAE management. Baseline irAE-related inpatient and outpatient visits were defined as the first inpatient or hospita-based outpatient visit with discharge diagnosis of any irAE of interest following confirmed ICI usage within 90 days prior to the baseline visit. Patients were followed for 90 days post baseline irAE-related inpatient discharge date or outpatient visit date to assess irAE-related inpatient admissions, all-cause inhospital mortality, ICI re-initiation, and to determine costs and healthcare resource utilization.